| Li, Lanfang |
| Active, not recruiting | 2 | 59 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Mantle Cell Lymphoma | 10/23 | 08/28 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 12/24 | 09/25 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
NCT04250324: Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma |
|
|
| Recruiting | 1 | 21 | RoW | BZ019 | Shanghai Cell Therapy Group Co.,Ltd, Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital | Large B-cell Lymphoma | 08/22 | 12/22 | | |
NCT04696432: A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma |
|
|
| Active, not recruiting | 1 | 7 | RoW | Prizloncabtagene autoleucel, C-CAR039 | Tianjin Medical University Cancer Institute and Hospital, Cellular Biomedicine Group Ltd. | Non-Hodgkin's B-cell Lymphoma | 07/23 | 12/23 | | |
NCT06318884: A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma |
|
|
| Not yet recruiting | 1 | 76 | RoW | SCTB35 injection, none other names | Sinocelltech Ltd. | Non-Hodgkin Lymphoma, B-cell | 10/26 | 12/27 | | |
NCT05607498: First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma |
|
|
| Recruiting | 1 | 150 | RoW | EMB07 | EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma | 10/25 | 03/26 | | |
